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ABSTRACT
Cells from Fanconi anemia (FA) patients are hypersensitive to alkylating agents and radiation traditionally used as
conditioning regimens for marrow cell transplantation, and patients experience serious toxicities. To reduce
toxicities, we used progressively lower doses of cyclophosphamide (CY) for conditioning. Here, we report the
results in 43 FA patients who received marrow transplantation from HLA-matched related donors (37 siblings and
6 other relatives). Conditioning consisted of 15 mg CY/kg/day for 4 days along with Mesna. Methotrexate and
cyclosporine were given for graft-versus-host disease (GVHD) prophylaxis. Forty patients (93%) are alive with a
median follow-up of 3.7 (range 0.6 to 7.9) years. One patient with primary graft failure was successfully retrans-
planted. Three of 4 patients with late graft failures were retransplanted, and 2 of those are alive; 1 died before a
secondmarrow graft. Twelve patients including 3with rejection had cytogenetic abnormalities in theirmarrow cells
before transplantation. Acute grade II-III and chronic GVHD (aGVHD, cGVHD) were seen in 17% and 28.5% of
patients, respectively. These results confirm and extend our previous observations that conditioning with 60 mg
CY/kg allows for sustained engraftment of HLA-matched related marrow grafts in most FA patients and is
associated with low toxicity, low incidences of aGVHD and cGVHD, and excellent long-term survival.
© 2007 American Society for Blood and Marrow Transplantation
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INTRODUCTION
Fanconi anemia (FA) is usually associated with
chromosomal instability and skeletal malformations.
In addition, patients with FA have a tendency to
progress to marrow failure and are at risk of develop-
ing acute myelogenous leukemia (AML), myelodys-
plastic syndromes (MDS), and epithelial malignancies
later in life [1]. Allogeneic marrow transplantation is
currently the only treatment able to restore normal
hematopoiesis and improve survival of these patients
[2]. A factor limiting success has been that FA cells
have a unique hypersensitivity to alkylating agents,raft ● Low-dose cyclophosphamide
which makes patients susceptible to serious regimen-
related toxicities. To reduce toxicities, we have ex-
plored progressively lower doses of cyclophosphamide
(CY) as a single conditioning agent for HLA-matched
related marrow grafts [3-5]. We published our early
experience in FA patients who received grafts after
either 80 mg/kg or 60 mg/kg of CY alone, and the
results demonstrated acceptable toxicity and a high
engraftment rate. A low rate of graft-versus-host dis-
ease (GVHD) was seen in patients conditioned with 60
mg CY/kg [6]. Here, we update the early experience in
23 patients and report data on 20 additional patients
given either genotypically HLA-identical (n  37) or1455
1456phenotypically HLA-matched (n  6) related marrow
grafts after conditioning with 60 mg/kg CY.
PATIENTS AND METHODS
Forty-three consecutive patients with FA and mar-
row failure received HLA-matched related marrow
grafts between July 1999 and October 2006. Patient
characteristics are shown in Table 1. The median
interval from diagnosis to transplantation was 25
(range: 1-180) months. The median number of previ-
ous blood transfusions was 6 (range: 0-151). Thirty-
seven patients had genotypically HLA-identical sib-
ling donors and 6 had phenotypically HLA-matched
donors (grandfather in 2, mother in 2, uncle in 1, and
cousin in 1). Among families of these 6 patients, con-
sanguinity was observed in 2. Complementation
groups were determined in 16 patients, of whom 12
had group A, 2 had group C, 1 had group G, and 1 had
group F. The diagnosis of FA was based on clinical
features and diepoxybutane (DEB)-induced chromo-
somal breakage. All donors had negative DEB tests for
FA. All patients were in the severe or moderately
severe aplastic phase of FA, and no patient had clear
evidence of MDS or acute leukemia, although 12
patients had cytogenetic abnormalities in their mar-
row cells. Patients were transplanted according to
Table 1. Characteristics of Patients
Characteristic
No. of patients (%) 43
Patient age, years, median (range) 9 (5-29)
Donor type, No. of patients (%)
HLA-identical siblings 37 (86)
HLA-phenotypical matched relative
other than siblings 6 (14)
Donor/recipient sex, No. of
patients (%)
Female/female 12
Female/male 10
Male/female 8
Male/male 13
Months from diagnosis of Fanconi
anemia to transplant,
median(range) 25 (1-180)
Hematologic parameters before
transplant, median (range)
Hemoglobin g/dL 8.8 (5.9-11.4)
Platelets  103/L 27,000 (6000-72,000)
Neutrophils  103/L 650 (102-2714)
Cytogenetic findings in marrow cells
(No. of patients)
Not done/no evaluable metaphases 11
Normal cytogenetics 20
Abnormal cytogenetics 12
Numbers of blood product transfusions
before transplant, median (range) 6 (0-151)
Nucleated marrow cells infused  108/kg
patient weight, median (range) 4.0 (1.7-7.3)Fred Hutchinson Cancer Research Center (FHCRC)
protocol 1228, approved by the institutional review
board (IRB) of the FHCRC (Seattle-USA) and Clinics
Hospital in Curitiba (Brazil). All patients signed in-
formed consents approved by the local IRBs.
Patients received 15 mg CY/kg/day, on days 4,
3, 2, and 1 before hematopoietic cell transplan-
tation (HCT), along with Mesna. GVHD prophylaxis
consisted of cyclosporine (CSP), 3 mg/kg/day, begin-
ning on day 1 and a short course of methotrexate
(MTX), 15 mg/m2 on day 1, and 10 mg/m2 on days
3, 6, and  11. All patients received bone marrow
grafts and were transplanted in single or double rooms
with high efﬁciency particulate air (HEPA). Forty-two
patients were transplanted in Curitiba and 1 patient in
Seattle. In the case of major ABO incompatibility, red
blood cells were removed from the marrow graft by
starch sedimentation. Patients seronegative for cyto-
megalovirus (CMV) were transfused with CMV-neg-
ative blood or leukodepleted blood products (Cu-
ritiba) or blood products from CMV-negative donors
(Seattle). Acyclovir prophylaxis for herpes simplex vi-
rus and varicella-zoster virus, trimethropim-sulfame-
thoxazole for Pneumocystis carinii pneumonia prophy-
laxis, and ﬂuconazole for prevention of yeast
infections were used in all patients. Weekly antigen-
emia testing for monitoring of CMV reactivation and
preemptive treatment with ganciclovir were done.
The median number of nucleated marrow cells in-
fused was 4 (range: 1.7-7.3)  108 cells/kg recipient
body weight. Acute GVHD (aGVHD), grades II-IV
was deﬁned using published criteria, and all patients
surviving21 days after HCT were considered at risk
[7]. Patients surviving 90 days were considered at
risk for chronic GVHD (cGVHD) [8]. Neutrophil
engraftment was deﬁned as a neutrophil count 500
 103/L for at least 3 consecutive days without
growth factor support. Time to platelet engraftment
was deﬁned as the ﬁrst of 3 consecutive days on which
the platelet counts were 20,000  103/L without
transfusions for 7 days. Primary graft failure was de-
ﬁned as failure to achieve a neutrophil count 500 
103/L by day 42. Secondary graft failure was deﬁned
as initial engraftment (neutrophils 500  103/L)
and subsequent decline to a neutrophil count 500 
103/L. Organ toxicity was deﬁned according to Na-
tional Cancer Institute (NCI) common toxicity crite-
ria, and mucositis according to published standards
[6]. Marrow donor engraftment was documented by
ABO typing in patients with red blood cell group
differences, chromosomal analysis in sex-mismatched
patient/donor pairs, and PCR for variable number
tandem repeat polymorphisms. Survival curves were
plotted using the method of Kaplan and Meier. Re-
sults were reported as of May 11, 2007.
C. M. Bonfim et al.
HLA-Matched Related Donor HCTs 1457RESULTS
Conditioning-Related Toxicities and Infections
Oral mucositis was noted among all patients (Table
2). The severity of mucositis was grade I in 4, II in 13,
IIIa in 19, IIIb in 6, and IV in 1 patient(s). Thirty patients
(69%) received all 4 doses of MTX, 12 patients received
3 doses because of mucositis, and 1 received only 2 doses
of MTX because of renal and hepatic failure. One pa-
tient developed grade II hemorrhagic cystitis.
No gastrointestinal toxicities were seen. Five pa-
tients developed mild to moderate hypertension while
on cyclosporine. Eight patients had positive antigen-
emia tests for CMV but none developed CMV disease.
Two patients had varicella zoster virus reactivation 1.5
years after transplantation.
One early death occurred in a 23-year-old man
who had received 150 blood transfusions and many
years of androgen treatment. He died on day 27
with multiorgan failure and fungal infection; he
showed neurologic complications, severe hepatic tox-
icity, and renal failure requiring dialysis. At the time of
death he had evidence of neutrophil engraftment but was
platelet transfusion-dependent. The autopsy showed
esophageal candidiasis, ﬁbrotic pericarditis with 500
mL of pericardial effusion, massive liver hemosider-
osis without venoocclusive disease, and pulmonary
hemorrhage.
Engraftment
Initial engraftment occurred in 41 of 42 evaluable
patients, while 1 patient had primary graft failure.
Table 2. Outcomes after Transplantation for Patients with Fanconi
Anemia Conditioned with Cyclophosphamide
Outcome No. of Pts (%)
Median years follow-up (range) 3.7 (0.6-7.9)
Mucositis, grade
I 4 (10)
II 13 (30)
III 25 (58)
IV 1 (2)
Graft failure
Primary 1 (2)
Late 4 (9)
Mortality
Day 100 1 (2)
1 year 1 (2)
Acute GVHD, grade
0 34 (81)
I 1 (2)
II 6 (15)
III-IV 1 (2)
Chronic GVHD
Extensive 10 (24)
Limited 2 (5)
None 29 (71)
Secondary malignancy 1 (2)
GVHD indicates graft-versus-host disease; Pts, patients.Median times to neutrophil and platelet engraftment
were 19 (range: 10-42) days and 21 (range: 14-33)
days, respectively. Overall, 37 patients had sustained
engraftment of donor cells, while 4 patients showed
late graft rejections. One of the 5 patients with graft
failure had mild dysplastic features in the marrow
before transplantation, 3 had chromosomal abnormal-
ities in marrow cells including monosomy 7, inv (3),
and dup (1), all had received preceding transfusions
(median 11, range: 6-101 units), 3 had grafts from
siblings, 1 from a grandfather, and 1 from a cousin,
and their nucleated marrow cell doses ranged from 3.4
to 64 (median 5.1)  108 cells/kg.
The patient without engraftment was a 9-year-old
male given a graft from his sister. He underwent (unsuc-
cessful) second transplantation from the same donor 150
days after the ﬁrst using conditioning with ﬂudarabine
(25 mg/m2/day for 5 days) and CY (15 mg/kg/day for 4
consecutive days). On day240 after the ﬁrst transplant
he received a third graft from another HLA-identical
sister after conditioning with busulfan, 4 mg/kg/day for
2 consecutive days, 200 cGy total body irradiation (TBI),
and antithymocyte globulin (rabbit ATG, Sangstat-Gen-
zyme), at a total dose of 4 mg/kg over 4 days. He had
complications including CMV reactivation, seizures re-
lated to cyclosporine toxicity, distal tubular acidosis, and
extensive cGVHD involving oral mucosa, liver, and
lungs. Thirty-three months after the ﬁrst transplant the
patient is well engrafted, with normal blood counts and
95% donor chimerism. Chronic GVHD disease has
been well controlled, and immunosuppression is gradu-
ally being tapered.
Among the patients with late graft failures, one
29-year-old female died on day 918 with pancytopenia
(the donor had declined a second marrow harvest).
Another patient received a second transplant from his
grandfather on day 258 after the ﬁrst HCT and is alive
6 years later with a white blood cell count of 2960/L,
a neutrophil count of 1500/L, hemoglobin of 17.4g/
dL, and platelets of 99,000/L. Chimerism analysis
showed 100% donor marrow cells. A third patient
rejected a graft from her 12-year-old cousin at 17
months, and received a successful second graft from
the same donor after ﬂudarabine, 25 mg/m2/day for 5
consecutive days, and CY, 15 mg/kg/day, for 4 con-
secutive days. She is alive and well 25 months after the
second HCT with engraftment and 90%-95% donor
chimerism. The fourth patient experienced graft fail-
ure on day 365; although she had normal cytoge-
netics before the ﬁrst HCT, her marrow cells showed
complex cytogenetic abnormalities before a second
HCT from her 16-year-old sister , this time using
peripheral blood stem cells, after CY, 20 mg/kg/day
for 4 consecutive days. She had rapid hematopoietic
recovery, experienced grade IV aGVHD on day 54,
had viral infections with CMV, herpes simplex, and
EBV, and died on day 75 after the second HCT.
C. M. Bonfim et al.1458The median proportion of donor cells among pe-
ripheral blood leukocytes in the surviving 40 patients
was 95 (range: 80-100)%. Acute GVHD, grade II, was
diagnosed in 6 of 42 evaluable patients after their ﬁrst
transplantation, and grade III was seen in 1 patient to
a total of 17% (Table 2). Twelve patients developed
cGVHD, which was limited in 2 and extensive in 10
patients (1 with quiescent, 5 with “de novo,” and 4
with progressive onset). One additional patient devel-
oped grade IV aGVHD after the second transplant,
and another, de novo cGVHD after the third trans-
plant. Six of the 13 patients with cGVHD are still
receiving immunosuppressive therapy.
Survival
Forty of the 43 patients (93%) are alive, with a
median follow-up of 3.7 (range: 0.6 -7.9) years (Fig-
ure 1). Two patients died as a consequence of graft
rejection and 1 because of regimen related toxicity. All
6 patients who received grafts from phenotypically
HLA-matched relatives are alive. At last contact, the
median Karnofsky performance score was 100 (range
80%-100)%; speciﬁcally, only 4 patients had scores of
100%.
DISCUSSION
Owing to its immunosuppressive properties
[9-11], the fact that it is nonmyeloablative [11], and its
lessened tendency to cause late malignancies com-
pared to radiation-based regimens [12-14], CY has
been a preferred conditioning regimen for patients
with aplastic anemia (AA) and FA treated by marrow
allografts. Initially, FA patients were conditioned with
the typical AA regimen of 200 mg CY/kg [15]; how-
ever, it was recognized soon that patients with FA
experienced more serious CY-related toxicities than
patients with other types of AA [16,17], probably from
Figure 1. Probability of survival among 43 patients with Fanconi
anemia conditioned with CY 60 mg/kg and given marrow grafts
from related donors.their poor ability for DNA repair after exposure to an
alkylating agent. We, therefore, began a systematic
study of CY dose reduction in FA patients undergoing
marrow allografts [3-6].
The current and previous [6] results in 43 FA
patients conditioned with 60 mg CY/kg showed that
this dose was well tolerated with the major toxicity
being oral mucositis (the combined result of CY and
posttransplantation MTX), although only 1 patient
had grade IV mucositis. Accordingly, day 100 and 1
year mortality rates were 2%, respectively. Results
suggested that 60 mg CY/kg was at the lower limit of
immunosuppression required for such allografts. Al-
though sustained donor engraftment was seen in 88%
(37 of 42) of evaluable patients, 12% either failed to
engraft (n  1) or experienced graft rejection after
initial engraftment (n  4). The exact causes of graft
failure/rejection in these 5 patients have remained
unknown, but could include sensitization to non-HLA
antigens by transfusions of blood products, as has been
described for patients transplanted for AA [15,18], the
emergence of myelodysplastic syndromes in 3 of the
patients with rejections, as suggested by chromosomal
abnormalities in 2 patients, phenotypic and not geno-
typic HLA-identity in 2 of the patients, or inadequate
CY-induced immunosuppression because of variations
in CY metabolism in individual patients. Four of the 5
patients had successful retransplantations, and 3 of
them are surviving, whereas 1 died of aGVHD. Per-
haps patients with chromosomal changes characteris-
tic of MDS, those with phenotypically HLA-matched
donors, and those with a history of extensive transfu-
sions might beneﬁt from the addition of ﬂudarabine to
60 mg CY/kg. Also, a better understanding of CY
metabolism in FA patients is needed.
Others have used different conditioning regimens.
Farzin et al. [19] conditioned 30 patients with FA by
combining CY, 20 mg/kg, and 400 cGy thoraco-
abdominal irradiation (TAI) before HLA-identical
sibling grafts. Five patients with chromosomal
changes in their marrow and 1 with a 5/6 HLA-
matched sibling were given more intensive condition-
ing with 20-40 mg CY/kg and 400-450 cGy TBI.
Additionally, all patients received horse ATG in the
peritransplantation period. Thirty-two patients were
given marrow, and 3 were given cord blood (from
siblings) grafts. Overall, 2 patients experienced graft
failure, and 29 of the 35 are surviving. Bitan et al. [20]
used 4 different conditioning regimens, variably con-
taining ﬂudarabine, CY, ATG, alemtuzumab, and
busulfan in preparation for HLA-matched grafts from
family members (n  5) or unrelated donors (n  2).
They encountered 1 graft failure, and reported that all
7 patients were alive and well. Wagner et al. [21]
reviewed CIBMTR data on 98 FA patients given un-
related grafts after a multitude of conditioning regi-
mens. They reported 52% survival among patients
HLA-Matched Related Donor HCTs 1459given ﬂudarabine-containing regimens, and 13%
among those not receiving ﬂudarabine. It was not clear
from the report whether ﬂudarabine beneﬁcially inﬂu-
enced graft failure and engraftment rates. However, the
authors state that day-100 platelet recovery was 74% in
patients given ﬂudarabine and 23% in those not receiv-
ing ﬂudarabine.
Seven current patients developed grade II or III
aGVHD, resulting in a cumulative incidence of 17%.
The only patient who developed grade IV aGVHD
did so after the second transplant. This compared
favorably to our previously reported incidences at
higher CY doses and those reported by others.
Guardiola et al. [22] reported a 42% overall cumula-
tive incidence of grades II-IV aGVHD, which rose to
62% in patients conditioned with 20 mg/kg CY and 5
Gy TAI. Ayas et al. [23] described 18% aGVHD in
patients given CY, 60 mg/kg and ATG. Others found
declines over time in the proportion of patients with
severe aGVHD [24]. The reasons for the very low
incidence of aGVHD in our series were not clear, but
could include less regimen-related tissue damage,
which allowed delivering all 4 scheduled MTX doses
in a majority of patients; MTX dosing has been shown
previously to be important in controlling the inci-
dence of GVHD [25]. Not surprisingly, the incidence
of cGVHD among current patients was also low
(28%), given that aGVHD and older patient age were
the most signiﬁcant risk factors for the development
of that complication [26]. Farzin et al. [19] observed
aGVHD in 8 of their 35 patients, whereas Bitan et al.
[20] saw aGVHD in 2 of 7 patients.
One patient with extensive cGVHD developed a
squamous cell carcinoma of the tongue 5 years after
transplant at the age of 12. The tumor was initially
resected, but at the time of this report the patient
has persistent disease. Longer follow-up is still
needed to determine the incidence of malignancies
in the surviving patients. Among our previously
reported experience in 62 FA patients, who were
conditioned with higher doses of Cy and followed
for up to 22 years after HCT, there were 5 cases of
squamous cell carcinoma of the tongue and 1 case of
colon cancer occurring between 4.9 and 11.8 years
after HCT [6]. Guardiola et al. [22] reported a 20%
incidence of head and neck cancer in patients given
CY  TAI who were followed for 10 years and a
53% incidence in patients followed for 15 years
[14,27]. Head and neck cancers have been described
both in FA patients who did and did not receive
HCT [1,14,27]. Farzin et al. [19] observed 2 cases of
squamous cell carcinoma, which was fatal in 1 case,
whereas the other case showed tumors both in
tongue and anus; these 2 tumors have been success-
fully treated, although a new carcinoma of the skin
has been diagnosed [20]. The CIBMTR publication
[21] did not comment on late tumors.In conclusion, 60 mg CY/kg is a well-tolerated
conditioning regimen with a sustained engraftment
rate in patients with uncomplicated FA given geno-
typically HLA-identical HCT. Acute GVHD and
cGVHD were relatively infrequent and overall sur-
vival excellent.
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